Fortitude Family Office’s Fennec Pharmaceuticals FENC Stock Holding History

Fortitude Family Office’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54	Buy	+5	New	+$41	﹤0.01%	2203

Other funds holding FENC

Hartford Financial Management Hartford, Connecticut $448M AUM 32.11% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return

Fortitude Family Office's FENC Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 5 shares worth $54. The stake represents ﹤0.01% of the portfolio and ranks #2203 among its holdings.

13 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Fortitude Family Office held 5 shares of Fennec Pharmaceuticals worth $54 as of Q2 2026.
Fennec Pharmaceuticals was a new Fortitude Family Office position in Q2 2026.
Fennec Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2203 holding.
13 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.